Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

Core Insights - Compass Therapeutics reported significant progress in 2025, particularly with its lead asset tovecimig achieving the primary endpoint in the COMPANION-002 Phase 2/3 study for biliary tract cancer [2] - The company anticipates transformative data releases for tovecimig's progression-free survival (PFS) and overall survival (OS) in April 2026, which could provide new treatment options for patients [2] - The financial position remains strong with $209 million in cash and marketable securities, expected to fund operations into 2028 [2][13] 2025 Accomplishments - Tovecimig successfully met the primary endpoint in the COMPANION-002 study for biliary tract cancer [2][5] - CTX-8371, a PD-1 x PD-L1 bispecific antibody, showed strong clinical activity with responses in heavily pre-treated patients [2] - Expansion cohorts for CTX-8371 are now open for enrollment in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) [4][5] 2026 Pipeline Updates - The analyses of key secondary endpoints from the COMPANION-002 study are expected in April 2026 [6] - A broader Phase 2 study of tovecimig in DLL4+ tumor types is set to initiate mid-2026 [6] - The IND application for CTX-10726 received FDA clearance, with enrollment for the Phase 1 study expected in Q1 2026 [5][14] Financial Results - The net loss for 2025 was $66.5 million, compared to $49.4 million in 2024, reflecting an increase in operational costs [10] - Research and development (R&D) expenses rose to $56.0 million, a 32% increase from $42.3 million in 2024, primarily due to manufacturing costs for tovecimig and CTX-10726 [11] - General and administrative (G&A) expenses increased to $16.9 million, up 12% from $15.1 million in 2024 [12] Cash Position - As of December 31, 2025, cash and marketable securities totaled $209 million, an increase of $82 million from $127 million in 2024 [13] - The company utilized $49 million in net cash for operating activities during 2025, offset by net proceeds from a public offering of $129 million [13]